Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T13:28:20.613Z Has data issue: false hasContentIssue false

Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: An exploratory analysis

Published online by Cambridge University Press:  18 June 2009

Johanna S. Paddison
Affiliation:
Division of Psychiatry and Medicine, Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
Jennifer S. Temel
Affiliation:
Harvard Medical School, Boston, Massachusetts Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts
Gregory L. Fricchione
Affiliation:
Division of Psychiatry and Medicine, Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
William F. Pirl*
Affiliation:
Division of Psychiatry and Medicine, Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
*
Address correspondence and reprint requests to: William Pirl, Massachusetts General Hospital Cancer Center, Yawkey 9A, 55 Fruit Street, Boston, MA 02114. E-mail: wpirl@partners.org

Abstract

Objective:

Fatigue is currently recognized as an undertreated symptom in cancer. To date the association between fatigue and inflammatory activation has not been examined in patients with advanced cancer. Our exploratory investigation considered whether variations in routinely available hematological parameters relate to the severity of fatigue reports.

Methods:

Fatigue, white blood cell differential, and hemoglobin concentration were assessed in 44 Stage IIIb and IV non-small-cell lung cancer (NSCLC) patients. Days of survival and the relative timing of treatment discontinuation were also recorded. Relationships between fatigue intensity and length of survival and between fatigue and hematological variables were examined using binomial and linear regressions respectively.

Results:

When we controlled for effects related to age, gender, and time until treatment termination, more intense fatigue was associated with shorter survival (β = −.34, p = .03). Lower hemoglobin concentrations were associated with more intense fatigue (β = −.36, p = .04). When we controlled for the effect attributable to hemoglobin, higher neutrophil (β = .43, p = .01) and monocyte (β = .31, p = .05) concentrations were associated with reports of more severe fatigue.

Significance of results:

This exploratory study provides empiric data showing that the severity of fatigue reported by advanced-stage NSCLC patients is significantly associated with length of survival. Consistent with existing data, linear regression identified a negative association between fatigue intensity and hemoglobin concentration. When we controlled for this effect, further linear regressions identified significant relationships between fatigue and blood concentrations of neutrophils and monocytes. Further, the magnitude of relationship between myeloid cell concentrations and fatigue was similar to the effect size identified for the relationship between hemoglobin and fatigue. Thus, the indirect measure of inflammatory state provided by routinely assessed myeloid cell counts appears to play as strong a role as the established variable, hemoglobin, in accounting for the fatigue reported by this sample of advanced-stage lung cancer patients.

Type
Original Articles
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Bower, J.E., Ganz, P.A., Aziz, N., et al. (2002). Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64, 604611.CrossRefGoogle ScholarPubMed
Collado-Hidalgo, A., Bower, J.E., Ganz, P.A., et al. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical Cancer Research, 12, 27592766.CrossRefGoogle ScholarPubMed
Curt, G.A. (2001). Fatigue in cancer. British Medical Journal, 322, 1560.CrossRefGoogle ScholarPubMed
Irwin, M.R. (2008). Human psychoneuroimmunology: 20 years of discovery. Brain, Behavior, and Immunity, 22, 129139.CrossRefGoogle ScholarPubMed
Jameson, J.L. & Johnson, B.E. (2005). Paraneoplastic syndromes: Endocrinologic/hematologic. In Harrison's Principles of Internal Medicine (16th ed.), Fauci, A.S., Hauser, S.L., Longo, D.L., et al. (eds.), pp. 566570. London: McGraw-Hill.Google Scholar
Kimel, M., Leidy, N.K., Mannix, S., et al. (2008). Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value in Health, 11, 5775.CrossRefGoogle ScholarPubMed
Krueger, J.M. & Majde, J.A. (2003). Humoral links between sleep and the immune system. Annals of the New York Academy of Sciences, 992, 920.CrossRefGoogle ScholarPubMed
Maier, S.F. & Watkins, L.R. (1998). Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review, 105, 83107.CrossRefGoogle ScholarPubMed
Ruka, W., Rutkowski, P., Kaminska, J., et al. (2001). Alterations of routine blood tests in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance. Annals of Oncology, 12, 14231432.CrossRefGoogle ScholarPubMed
Temel, J.S., Jackson, V.A., Billings, J.A., et al. (2007). Phase II study: Integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. Journal of Clinical Oncology, 25, 23772382.Google Scholar
Watkins, L.R. & Maier, S.F. (1999). Implications of immune-to-brain communication for sickness and pain. Proceedings of the National Academy of Sciences, USA, 96, 77107713.CrossRefGoogle ScholarPubMed